Han W Tun

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models
    Zhimin Li
    Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, United States of America
    PLoS ONE 8:e71754. 2013
  2. pmc Pathway analysis of primary central nervous system lymphoma
    Han W Tun
    Department of Hematology and Oncology, Mayo Clinic Jacksonville, FL 32224, USA
    Blood 111:3200-10. 2008
  3. pmc Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma
    Christina A von Roemeling
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida 32224, USA
    Clin Cancer Res 19:2368-80. 2013
  4. pmc Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma
    Liuyan Jiang
    Department of Pathology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Int J Clin Exp Pathol 5:72-6. 2012
  5. pmc Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers
    Simon J Cooper
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Mol Cancer Ther 11:2105-15. 2012
  6. pmc Selective central nervous system tropism of primary central nervous system lymphoma
    Liuyan Jiang
    Department of Hematology Oncology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Int J Clin Exp Pathol 3:763-7. 2010
  7. pmc Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies
    Laura A Marlow
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL 32224, USA
    J Cell Sci 125:4253-63. 2012
  8. doi request reprint Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)
    Tait D Shanafelt
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
    Blood 121:4137-41. 2013
  9. pmc Pathway signature and cellular differentiation in clear cell renal cell carcinoma
    Han W Tun
    Department of Hematology Oncology, Mayo Clinic, Jacksonville, Florida, United States of America
    PLoS ONE 5:e10696. 2010
  10. doi request reprint Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma
    Rajesh K Shetty
    Florida Eye Specialists, Jacksonville, Florida 32256, USA
    Ocul Immunol Inflamm 18:110-2. 2010

Collaborators

Detail Information

Publications11

  1. pmc Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models
    Zhimin Li
    Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, United States of America
    PLoS ONE 8:e71754. 2013
    ..It can induce significant biological changes in tumor-associated macrophages, which likely play a major role in its therapeutic activity against CNS lymphoma. POM should be further evaluated in clinical trials. ..
  2. pmc Pathway analysis of primary central nervous system lymphoma
    Han W Tun
    Department of Hematology and Oncology, Mayo Clinic Jacksonville, FL 32224, USA
    Blood 111:3200-10. 2008
    ..The gene expression signature discovered in our study may represent a true "CNS signature" because we contrasted PCNSL with wide-spectrum non-CNS DLBCL on a genomic scale and performed an in-depth bioinformatic analysis...
  3. pmc Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma
    Christina A von Roemeling
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida 32224, USA
    Clin Cancer Res 19:2368-80. 2013
    ..S. Food and Drug Administration (FDA)-approved regimens...
  4. pmc Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma
    Liuyan Jiang
    Department of Pathology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Int J Clin Exp Pathol 5:72-6. 2012
    ..It is characterized by a very aggressive clinical course, and a widespread multifocal involvement of the CNS. Our case shows that a DLBCL/BL can manifest in the CNS alone without any systemic involvement...
  5. pmc Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers
    Simon J Cooper
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Mol Cancer Ther 11:2105-15. 2012
    ..Combinatorial treatment with romidepsin and decitabine in drug resistant tumors is a promising treatment strategy. Moreover, recombinant sFRP1 may be a novel therapeutic strategy for cancers with suppressed sFRP1 expression...
  6. pmc Selective central nervous system tropism of primary central nervous system lymphoma
    Liuyan Jiang
    Department of Hematology Oncology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Int J Clin Exp Pathol 3:763-7. 2010
    ..We did not find any evidence of lymphoma at the site of implantation or other locations. The findings are consistent with highly selective tropism of PCNSLforthe CNS and its vasculature...
  7. pmc Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies
    Laura A Marlow
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL 32224, USA
    J Cell Sci 125:4253-63. 2012
    ..This new paradigm also suggests caution in relation to current dogma focused upon reactivation of FoxO3a as a therapeutic strategy against cancers harboring active PI3-K and Akt signaling pathways...
  8. doi request reprint Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)
    Tait D Shanafelt
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
    Blood 121:4137-41. 2013
    ..These novel data showing repair of T-cell defects provide proof-of-principle that lenalidomide-based consolidation after CIT could have a beneficial clinical and immunologic role in CLL...
  9. pmc Pathway signature and cellular differentiation in clear cell renal cell carcinoma
    Han W Tun
    Department of Hematology Oncology, Mayo Clinic, Jacksonville, Florida, United States of America
    PLoS ONE 5:e10696. 2010
    ..Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer. The purpose of this study is to define a biological pathway signature and a cellular differentiation program in ccRCC...
  10. doi request reprint Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma
    Rajesh K Shetty
    Florida Eye Specialists, Jacksonville, Florida 32256, USA
    Ocul Immunol Inflamm 18:110-2. 2010
    ..The patient had a complete remission within 3 months of starting rituximab therapy. A recurrence 6 months later remitted with a second round of rituximab therapy and the patient remained tumor-free at 1 year...
  11. doi request reprint A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin
    Jeremy T Larsen
    Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leuk Lymphoma 54:1713-8. 2013
    ..Median progression-free survival (PFS) was 11 months and 2-year PFS was 40%. We conclude that the reduced-intensity conditioning regimen of cladribine, thiotepa and ATG achieved excellent donor chimerism with acceptable toxicity...